Live
- Exciting Return of Santosh Trophy Football Tournament Kicks Off in Hyderabad
- Head Constable Dies by Suicide, Cites harssament by wife and inlaws
- Delhi BJP claims AAP govt will never pay women allowance like in Punjab
- India is 'Mother of Democracy': PM Modi
- ‘One nation, one election’ will undermine India’s federal structure: Mehbooba Mufti
- Vikram collaborates with director Madon Ashwin for ‘Chiyaan63’
- ‘Bachhala Malli’ trailer heightens anticipation
- Karnataka quota row: Backward Class forum chief warns Lingayat seer over 'tinkering with reservations'
- Tight security arrangements at Group-II examination centers District SP
- Alia Bhatt captures attention in white
Family member suffering from fatty liver disease? You may be at similar risk
Close relatives of people with metabolic-associated fatty liver disease have a higher risk of developing liver cancer and dying from liver-related diseases, according to a new study.
New Delhi: Close relatives of people with metabolic-associated fatty liver disease have a higher risk of developing liver cancer and dying from liver-related diseases, according to a new study.
It means that family members could also benefit from the lifestyle advice that is currently only given to patients, the researchers said in the study published in The Journal of Hepatology.
People with metabolic-associated fatty liver disease (MASLD, formerly known as NAFLD) have an elevated risk of developing and dying from liver cancer.
MASLD is now the main reason why the number of people developing liver cancer has risen so sharply.
However, researchers at Karolinska Institutet in Sweden now show that close relatives and partners also have an increased risk of developing liver cancer and advanced liver disease.
“Our findings indicate that patients with MASLD should not be treated separately,” said Fahim Ebrahimi, doctor and researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet.
“Our study also suggests that relatives with metabolic risk factors such as diabetes mellitus may benefit from early screening for MASLD,” he added.
The researchers based their study on the ESPRESSO cohort, which contains data on all liver biopsies taken in Sweden from 1965 up to the present.
They identified almost 12,000 people with biopsy-proven MASLD. After matching each person with up to five comparators from the general population they identified first-degree relatives (parents, siblings and children) and partners for both groups.
The study included nearly 250,000 first-degree relatives and 57,000 partners.
Over an average follow-up period of 17.6 years, with some individuals being followed for up to 50 years, the researchers found that first-degree relatives of MASLD patients were 80 per cent more likely to develop liver cancer than the controls.
However, as liver cancer is a relatively rare disease, the absolute increase in risk is much lower: 0.11 per cent over 20 years, according to the researchers.
The researchers also found that partners of patients with MASLD were more likely to develop severe liver disease (such as cirrhosis) and to die from liver-related causes.
“Our findings confirm that there is a clear familial risk of MASLD and that a shared lifestyle is an important factor in its development,” says Dr Ebrahimi.
